BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fiedler F, Ayasse D, Rohmeiss P, Gretz N, Rehbein C, Keim V. The endothelin antagonist bosentan does not improve survival in severe experimental pancreatitis in rats. Int J Pancreatol. 1999;26:147-154. [PMID: 10732291 DOI: 10.1385/ijgc:26:3:147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Fitzner B, Brock P, Holzhüter SA, Nizze H, Sparmann G, Emmrich J, Liebe S, Jaster R. Synergistic growth inhibitory effects of the dual endothelin-1 receptor antagonist bosentan on pancreatic stellate and cancer cells. Dig Dis Sci 2009;54:309-20. [PMID: 18612819 DOI: 10.1007/s10620-008-0366-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
2 Andrzejewska A, Dlugosz JW, Augustynowicz A. Effect of endothelin-1 receptor antagonists on histological and ultrastructural changes in the pancreas and trypsinogen activation in the early course of caerulein-induced acute pancreatitis in rats. World J Gastroenterol 2005; 11(8): 1115-1121 [PMID: 15754391 DOI: 10.3748/wjg.v11.i8.1115] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
3 Martignoni ME, Ceyhan GO, Ayuni E, Kondo Y, Zimmermann A, Büchler MW, Friess H. Endothelin receptor antagonists are not beneficial in the therapy of acute experimental pancreatitis. Langenbecks Arch Surg. 2004;389:184-192. [PMID: 15127205 DOI: 10.1007/s00423-004-0461-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]